For decades the standard of care for glioblastoma has scarcely moved. The Morizzo Foundation and INFORMITON are joining forces to change that — bringing a different kind of intervention to patients ready to walk a new road.
A diagnosis of GBM should never be the end of possibility. We owe these patients more than what medicine has offered for forty years.
SENTINEL X is the flagship technology of INFORMITON, an independent company specializing in biological intelligence and supramolecular diagnostics. At its heart is a deceptively simple idea: living systems exchange information not only through chemistry, but through the physics of light and sound themselves.
SENTINEL X engineers that exchange across two complementary channels. The first is photonic — precisely altering the energy states of photons, most often in the near-infrared range, to create information-laden interactions that biological systems can recognize, respond to, and act upon. The second is acoustic — formulated audio frequencies designed to evoke quantum tunneling events at the supramolecular scale.
Quantum tunneling is not a novelty of the laboratory. It is the same mechanism nature uses every day: in the cryptochrome proteins of migratory birds, where quantum effects enable navigation by the Earth's magnetic field, and in enzymes, where tunneling allows complex biochemical reactions to proceed at speeds and accuracies that classical chemistry alone cannot explain. SENTINEL X applies this principle deliberately — using sound, as nature uses it, as a carrier of biological information.
The intent is not to replace the standard of care. It is to inform it — to give the body its own voice in the conversation.
Non-invasive and non-pharmacological. No compound introduced into the body. The intervention is information, carried by photons and by formulated acoustic frequencies.
Biology operates above the level of single molecules, in cooperative arrangements that respond to subtle cues. SENTINEL X is designed to speak that language.
The protocol runs alongside oncology standard of care, not in place of it — supporting the patient's own systems while clinicians do their work.
Sessions are calm, quiet, and brief. No needles. No infusions. No hospital stays.
Glioblastoma is uniquely difficult because the tumor environment is exceptionally good at resisting external therapies — chemotherapy, radiotherapy, and targeted agents alike. We refer to this as anti-cancer resistance: the tumor's capacity to evade or blunt the interventions clinicians introduce.
SENTINEL X is designed to work at a different layer. Rather than introducing another external agent into a system already practiced at resisting them, it uses targeted photonic interaction and formulated acoustic frequencies — the same physical mechanisms biology already relies on for navigation, signaling, and high-speed enzymatic action — to support the patient's own regulatory architecture, including pathways involving the Vegetative Nervous System (VNS) and stress-response signaling, with the aim of reducing the conditions under which anti-cancer resistance flourishes.
An initial supramolecular diagnostic profile establishes the patient's baseline. No invasive procedures. No new compounds.
Targeted near-infrared photonic interactions and formulated audio frequencies are delivered in calm, brief sessions designed to inform the body's own regulatory pathways through the same physics nature already uses.
The protocol runs alongside the patient's existing oncology regimen. Clinicians remain in full command of the standard of care.
Indicators including stress-response markers (cortisol among them), symptom burden, and quality-of-life measures are tracked throughout.
A patient who had been told to plan for months found, over the course of the protocol, that the days began to belong to them again — energy, presence, and a quality of life their family describes as the unexpected gift inside a diagnosis that offered none.
▸ Replace with confirmed narrative
After recurrence, the standard story narrows. For this patient and their family, what changed was not the diagnosis but the texture of the time inside it — clearer thinking, calmer nights, and a sense of partnership in their own care.
▸ Replace with confirmed narrative
The Morizzo Foundation and INFORMITON are jointly opening enrollment to a limited cohort of patients facing glioblastoma who wish to participate in the SENTINEL X early access program.
Drawing on the Foundation's mission to remove financial barriers to care and INFORMITON's commitment to compassionate access, the joint program covers the cost of SENTINEL X protocols for accepted patients. Because the technology can be delivered remotely, no travel is required — patients participate from wherever they are, alongside their existing oncology team.
No patient should be priced out of hope.
Every patient accepted into the program is supported by both organizations from intake through follow-up — with their clinical team kept fully in the loop at every step.
If you or someone you love is facing glioblastoma and would like to be considered for the joint program, share a one-minute video. Tell us who you are, where you are in your journey, and why you are reaching out. Your story will be received personally by the team.
Up to 1 minute · Record in browser or use your phone's camera